Digital Aria Co Ltd
HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrica… Read more
Digital Aria Co Ltd - Asset Resilience Ratio
Digital Aria Co Ltd (115450) has an Asset Resilience Ratio of 1.12% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Digital Aria Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Digital Aria Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩2.54 Billion | 1.12% |
| Total Liquid Assets | ₩2.54 Billion | 1.12% |
Asset Resilience Insights
- Limited Liquidity: Digital Aria Co Ltd maintains only 1.12% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Digital Aria Co Ltd Industry Peers by Asset Resilience Ratio
Compare Digital Aria Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Digital Aria Co Ltd (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Digital Aria Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 17.19% | ₩37.77 Billion | ₩219.79 Billion | +1.07pp |
| 2023-12-31 | 16.11% | ₩32.35 Billion | ₩200.79 Billion | -17.97pp |
| 2022-12-31 | 34.08% | ₩63.95 Billion | ₩187.64 Billion | -18.90pp |
| 2021-12-31 | 52.98% | ₩100.51 Billion | ₩189.71 Billion | +29.37pp |
| 2020-12-31 | 23.61% | ₩28.79 Billion | ₩121.94 Billion | -10.90pp |
| 2019-12-31 | 34.51% | ₩48.15 Billion | ₩139.52 Billion | +18.85pp |
| 2018-12-31 | 15.66% | ₩16.85 Billion | ₩107.66 Billion | +6.24pp |
| 2017-12-31 | 9.42% | ₩5.91 Billion | ₩62.71 Billion | +0.55pp |
| 2016-12-31 | 8.87% | ₩4.58 Billion | ₩51.65 Billion | +0.93pp |
| 2015-12-31 | 7.94% | ₩4.00 Billion | ₩50.35 Billion | -4.02pp |
| 2014-12-31 | 11.96% | ₩7.00 Billion | ₩58.52 Billion | +11.37pp |
| 2013-12-31 | 0.59% | ₩216.00 Million | ₩36.69 Billion | +0.01pp |
| 2012-12-31 | 0.58% | ₩313.70 Million | ₩54.32 Billion | -6.93pp |
| 2011-12-31 | 7.51% | ₩4.67 Billion | ₩62.23 Billion | -- |